AstraZeneca PLC - American Depositary Shares (NQ:AZN)

It will take a lot, but this goal isn't out of reach for these stocks.

2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years ↗

March 01, 2024

A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.

11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗

February 28, 2024

Via Benzinga

3 Inflation-Resilient Stocks to Weather the Economic Turbulence ↗

February 28, 2024

These are the undervalued inflation-resilient stocks to buy as they represent companies that have strong fundamentals.

Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.

Check Out What Whales Are Doing With AZN ↗

February 16, 2024

Via Benzinga

Earnings Scheduled For February 8, 2024 ↗

February 08, 2024

Via Benzinga

EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic, Animal Studies Shows ↗

February 28, 2024

Vivani Medical unveils preclinical data on NPM-115, a twice-yearly exenatide subdermal implant for weight loss. Achieving a 20% reduction in high-fat diet-induced obese mice, comparable to Novo...

Via Benzinga

Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors ↗

February 26, 2024

Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.

Via Benzinga

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

February 23, 2024

From AstraZeneca

Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.

Move Over Magnificent 7, Say Hello to the GRANOLAS ↗

February 22, 2024

FDA greenlights AstraZeneca's Tagrisso combo for advanced EGFRm NSCLC. FLAURA2 Phase 3 trial results reveal a 38% reduction in progression risk with Tagrisso plus chemo, outperforming monotherapy....

Why AstraZeneca Stock Is Trading Higher Tuesday ↗

February 20, 2024

Via Benzinga

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

February 19, 2024

From AstraZeneca

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

February 19, 2024

From AstraZeneca

We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft...

Cruising For A Bruising ↗

February 18, 2024

Via Talk Markets

Topics Economy

Week In Review: LianBio To Close Operations; Will Pay $528 Million To Shareholders ↗

February 17, 2024

LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its...

Via Talk Markets

TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer

February 16, 2024

From AstraZeneca

Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness ↗

February 15, 2024

Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive.

7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution ↗

February 14, 2024

Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.

Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report ↗

February 13, 2024

Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months. ↗

February 13, 2024

There's more for investors to get excited about in the biopharma world than just weight-loss drugs.

This Analyst Slightly Lowers AstraZeneca Forecast Amid Earnings Concerns, Although Still Bullish on Future Growth Potential ↗

February 12, 2024

AstraZeneca reported Q4 2023 sales of $12.02B, up 7%, below consensus. Excluding COVID-19 drugs, revenue increased by 16%. Core EPS was $1.45, missing consensus. BMO Capital maintains Outperform...

Via Benzinga

AstraZeneca Leads The FTSE Lower On Barclay’s Downgrade ↗

February 12, 2024

The pharmaceutical sector saw a decline of 1.6%, with AstraZeneca dropping 2.4% after Barclays lowered its price target for the stock.

Via Talk Markets

From Slack To Surveillance: Here's How Companies Monitor Your Communications With AI ↗

February 10, 2024

In a move reminiscent of George Orwell's surveillance dystopia, companies are now deploying artificial intelligence (AI) to monitor communications on platforms like Slack and Microsoft Teams.

Via Benzinga

Topics Artificial Intelligence

Got $5,000? These 3 Stocks Are Near Their 52-Week Lows and Are Underrated Buys ↗

February 10, 2024

These stocks all trade at less than 17 times their future expected earnings.

AZN earnings call for the period ending December 31, 2023.

AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript ↗

February 08, 2024

Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

Topics Earnings

February 08, 2024

Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.

Via Benzinga

How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month ↗

February 08, 2024

Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.

Via Investor's Business Daily

AstraZeneca Stock Tumbles After Q4 Performance - Here's Why ↗

February 08, 2024

AstraZeneca Q4 2023: $12.02 billion sales, 7% Y/Y growth, fueled by global demand for cancer drugs. Excluding COVID-19 meds, revenue rises 16%. CEO Soriot projects low double-digit growth in 2024.

Via Benzinga

AstraZeneca Downgraded On "Underwhelming" Q4 Earnings ↗

February 08, 2024

AZN stock took a header early Thursday after a mixed Q4 report and a downgrade to sell on "thoroughly underwhelming" results.

Via Investor's Business Daily

AstraZeneca Full year and Q4 2023 Financial Results

February 08, 2024

From AstraZeneca